Open AccessPharmacodynamics of FUT-175 Anticoagulant in Adsorbent Plasma Perfusion
Author(s) -
Z Yamazaki,
M Hiraishi,
Fumihiko Kanai,
Akemi Noda,
Yasuo Idezuki,
Nozomu Inoue
Publication year - 1989
Publication title -
asaio transactions
Language(s) - English
Resource type - Journals
eISSN - 2375-0952
pISSN - 0889-7190
DOI - 10.1097/00002480-198907000-00128
Subject(s) - heparin , anticoagulant , hemoperfusion , chemistry , perfusion , chromatography , pharmacodynamics , extracorporeal , antithrombin , anesthesia , pharmacokinetics , medicine , pharmacology , hemodialysis , surgery , biochemistry
FUT, a new synthetic protease inhibitor, has been used recently in hemodialysis as an anticoagulant in patients with bleeding tendencies. As some new adsorbents require alternatives to heparin because of their strong adsorbing capacity for heparin, plasma perfusion with FUT anticoagulation was pharmacodynamically investigated. Blood was pumped from a dog (QB = 50-70 ml/min) into a plasma separator. The separated plasma (QP = 10-20 ml/min) passed through an adsorbent column and was reinfused into the blood that had passed through the plasma separator. FUT was continuously infused, at a flow rate of 50 mg/hr, into the blood as it left the dog and entered the extracorporeal circuit. Blood and plasma samples were taken as it exited the dog (S1), before and after the adsorbent column (S2, S3), and before reinfusion into the dog (S4). Except for that done with a charcoal-column, adsorbent plasma perfusion went well and the dog tolerated the procedure. FUT levels in S2, S3, and S4 provided anticoagulation. However, as the FUT levels in S1 remained negligible, the dog's coagulation time was within normal limits. In conclusion, FUT was pharmacodynamically proven to be a safe and reasonable anticoagulant for adsorbents that adsorb large amounts of heparin and for patients with bleeding tendencies.